Company / SG&A Expense
Protagonist Therapeutics, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$44.9M
FY2025
5-year range
$27.2M / $44.9M
FY2021-FY2025
Trend
+3.2%
vs FY2024
Sector context
#166 of 213
Health Care
What the data says
Protagonist Therapeutics, Inc.'s sg&a expense of $45M is lower than 78% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 9 consecutive years, from $7M in FY2016 to $45M in FY2025.
Based on SEC 10-K filings.
$45M in FY2025 with a 5-year CAGR of +19.2%.
Increased from $33M to $45M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +12.2%
- 5-Year CAGR
- +19.2%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 213This company $44.9M Sector average $722.3M
▼
-93.8% below sector average
Key checks
Key Insights
- Protagonist Therapeutics, Inc.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +19.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 3.2% year-over-year.
- Ranks #166 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 4.66 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.9M | +3.2% |
| FY2024 | $43.5M | +29.8% |
| FY2023 | $33.5M | +5.5% |
| FY2022 | $31.7M | +16.7% |
| FY2021 | $27.2M | +45.9% |
| FY2020 | $18.6M | +18.3% |
| FY2019 | $15.7M | +15.0% |
| FY2018 | $13.7M | +16.3% |
| FY2017 | $11.8M | +69.2% |
| FY2016 | $7.0M | +134.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026